Mycoplasma and cancer: in search of the link
Mycoplasma and cancer: in search of the link |
|
https://doi.org/10.18632/oncotarget.264
Melissa B. Rogers
|
| 271-273 |
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs |
|
https://doi.org/10.18632/oncotarget.265
Ingeborg M.M. van Leeuwen,
and Sonia Laín
|
| 274-276 |
A stressful life (or death): Combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability
A stressful life (or death): Combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability |
|
https://doi.org/10.18632/oncotarget.266
Paul Workman,
and Faith E. Davies
|
| 277-280 |
The “Infectious” Nature of Human Prostate Cancer: A Cautionary Note
The “Infectious” Nature of Human Prostate Cancer: A Cautionary Note |
|
https://doi.org/10.18632/oncotarget.267
Karen S. Sfanos,
and John T. Isaacs
|
| 281-283 |
Enhancing proteotoxic stress as an anticancer strategy
Enhancing proteotoxic stress as an anticancer strategy |
|
https://doi.org/10.18632/oncotarget.268
Steven Grant
|
| 284-286 |
Detecting and monitoring lymphoma with high-throughput sequencing
Detecting and monitoring lymphoma with high-throughput sequencing |
|
https://doi.org/10.18632/oncotarget.270
Harlan Robins
|
| 287-288 |
Association of Mycoplasma hominis infection with prostate cancer
Association of Mycoplasma hominis infection with prostate cancer |
|
https://doi.org/10.18632/oncotarget.256
Yulia A. Barykova,
Denis Yu. Logunov,
Maxim M. Shmarov,
Andrei Z. Vinarov,
Dmitry N. Fiev,
Natalia A. Vinarova,
Irina V. Rakovskaya,
Patricia Stanhope Baker,
Inna Shyshynova,
Andrew J. Stephenson,
Eric A. Klein,
Boris S. Naroditsky,
Alexander L. Gintsburg,
and Andrei V. Gudkov
|
| 289-297 |
Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting
Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting |
|
https://doi.org/10.18632/oncotarget.261
Aman P. Mann,
Rohan C. Bhavane,
Anoma Somasunderam,
Brenda Liz Montalvo-Ortiz,
Ketan B. Ghaghada,
David Volk,
René Nieves-Alicea,
K. Stephen Suh,
Mauro Ferrari,
Ananth Annapragada,
David G. Gorenstein,
and Takemi Tanaka
|
| 298-304 |
Caveolin-1 in sarcomas: friend or foe?
Caveolin-1 in sarcomas: friend or foe? |
|
https://doi.org/10.18632/oncotarget.255
Miguel Sáinz-Jaspeado,
Juan Martin-Liberal,
Laura Lagares-Tena,
Silvia Mateo-Lozano,
Xavier Garcia del Muro,
and Oscar M. Tirado
|
| 305-312 |
The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth
The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth |
|
https://doi.org/10.18632/oncotarget.259
Patrick Schmidt,
and Hinrich Abken
|
| 313-320 |
INPP4B: the New Kid on the PI3K Block
INPP4B: the New Kid on the PI3K Block |
|
https://doi.org/10.18632/oncotarget.260
Irina U. Agoulnik,
Myles C. Hodgson,
Wayne A. Bowden,
and Michael M. Ittmann
|
| 321-328 |
Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma
Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma |
|
https://doi.org/10.18632/oncotarget.263
John M. Koomen,
and Keiran S. M. Smalley
|
| 329-335 |
Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers |
|
https://doi.org/10.18632/oncotarget.262
Ryan B. Corcoran,
Jeffrey Settleman,
and Jeffrey A. Engelman
|
| 336-346 |
Mitochondrial Compartmentalized Protein Folding and Tumor Cell Survival
Mitochondrial Compartmentalized Protein Folding and Tumor Cell Survival |
|
https://doi.org/10.18632/oncotarget.273
Dario C. Altieri
|
| 347-351 |
